What one share of Alnylam Pharmaceuticals holds
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi.
Alnylam Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $34.64 |
|---|---|
| Profit | $5.59 |
| Capex (buildings and equipment) | $0.66 |
| Free cash flow | $5.91 |
| Cash and investments | $12.77 |
| Book value | $10.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $2.41 | −$1.14 | $0.12 | −$1.85 | — | $4.25 |
| 2010 | $2.38 | −$1.04 | $0.11 | −$2.12 | — | $3.74 |
| 2011 | — | −$1.36 | $0.03 | −$2.08 | — | $2.76 |
| 2012 | — | −$2.11 | $0.17 | −$2.46 | — | $2.55 |
| 2013 | — | −$1.45 | $0.07 | −$1.18 | — | $4.24 |
| 2014 | — | −$4.85 | $0.12 | −$2.35 | — | $12.13 |
| 2015 | — | −$3.45 | $0.15 | −$2.41 | — | $14.86 |
| 2016 | $0.55 | −$4.79 | $0.75 | −$4.35 | — | $10.71 |
| 2017 | $0.99 | −$5.42 | $1.15 | −$5.38 | — | $17.72 |
| 2018 | $0.74 | −$7.57 | $1.26 | −$6.85 | — | $12.87 |
| 2019 | $2.01 | −$8.11 | $1.28 | −$3.83 | — | $12.82 |
| 2020 | $4.29 | −$7.46 | $0.61 | −$5.96 | — | $8.73 |
| 2021 | $7.13 | −$7.20 | $0.64 | −$6.06 | — | $4.89 |
| 2022 | $8.53 | −$9.30 | $0.59 | −$5.04 | — | −$1.28 |
| 2023 | $14.64 | −$3.52 | $0.50 | $0.34 | — | −$1.75 |
| 2024 | $17.61 | −$2.18 | $0.27 | −$0.33 | — | $0.52 |
| 2025 | $27.58 | $2.33 | $0.44 | $3.46 | — | $5.96 |
Common questions about Alnylam Pharmaceuticals
How much does one share of Alnylam Pharmaceuticals earn?
Over the last 12 months, each share of Alnylam Pharmaceuticals earned $5.59 of profit on $34.64 of sales, keeping about 16¢ of every $1 (profit margin).
Does Alnylam Pharmaceuticals pay a dividend?
Alnylam Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Alnylam Pharmaceuticals’s book value per share?
Alnylam Pharmaceuticals’s book value is $10.13 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Alnylam Pharmaceuticals have?
Each share of Alnylam Pharmaceuticals has $12.77 of cash and investments, as of June 30, 2026.
What is Alnylam Pharmaceuticals’s free cash flow per share?
$5.91 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Alnylam Pharmaceuticals bought back shares?
Alnylam Pharmaceuticals’s share count rose about 223% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.